RE:Halt TradingHopefully reinstatement will come from this. Abattis Announces Refiling of Financial Statements and MD&A
As a result of a review by the British Columbia Securities Commission, the Company is issuing the following press release to clarify our disclosure.
VANCOUVER, BRITISH COLUMBIA / July 28, 2020 / Abattis Bioceuticals Corp. (the “Company” or “Abattis“) (CSE:ATT) (OTC:ATTBF).
The Company has filed amended financial statements for the year ended September 30, 2018 and amended management’s discussion and analysis for the year ended September 30, 2018 and the three and nine months ended June 30, 2019 (collectively, the “Amended Filings”).
The amended Financial Statements for the year ended September 30, 2018 were refiled to:
1. provide further disclosure respecting the investment in CannaNUMUS Blockchain Inc
(“CannaNUMUS”); and
2. provide further disclosure respecting our issued share capital.
The amended management’s discussion and analysis for the year ended September 30, 2018 was refiled to:
1. provide further disclosure respecting shares issued to consultants, directors and employees of the Company;
2. provide further disclosure respecting the fair value consideration provided by the Company in connection with its acquisition of GT Therapeutics Corporation;
3. provide further disclosure respecting the Company’s investment in CannaNUMUS;
4. provide further disclosure respecting license fees paid in relation to Gabriola Green Farms Inc.
(“Gabriola”);
5. provide disclosure respecting the status the construction work completed on Gabriola’s facility;
6. provide further disclosure on the loss of $51,656,606 for the three months ended September 30, 2018; and
7. provide further disclosure respecting transactions with related parties.
The amended management’s discussion and analysis for the three and nine months ended June 30, 2019 was refiled to:
1. provide further disclosure respecting quarterly results; and
2. provide further disclosure respecting transactions with related parties.